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mated to currently suffer from OAB across the ﬁve countries. An
estimated 2.5m also have symptoms of urge incontinence. By
2020, 2.1m additional males are expected to be affected by
OAB. The average health care cost associated with managing
these patients ranged from €200 in the UK to €732 in Italy. The
total cost of OAB in males aged >40 were estimated to be €1.7
billion in 2005: €412m in Germany; €607m in Italy; €350 in
Spain; €71m in Sweden and €231 in the UK. By 2020, the total
cost of OAB in males is expected to increase to €2 billion. This
compares with a total burden of €4.1 billion in 2005 and pro-
jected total burden of €5.2 billion in 2020. DISCUSSION: The
burden of OAB in males was 40% of the total burden in the
overall population aged > 40. The economic burden is likely 
to increase in line with our prevalence forecasts. Since many
males do not seek treatment, the future cost burden may be
underestimated.
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OBJECTIVE: To determine characteristics related to lost pro-
ductivity in working adults with overactive bladder (OAB) using
data from a large US multicenter trial. METHODS: Baseline data
were obtained from 2770 participants in the Multicenter Assess-
ment of Transdermal Therapy in Overactive Bladder with Oxy-
butynin (MATRIX). Productivity was assessed using the Work
Productivity Questionnaire (WPQ), a modiﬁed version of the
Work Limitations Questionnaire (WLQ) which captures physi-
cal, mental (concentration), time (interruptions and adherence to
a schedule), and output (ability to handle workload) domains
related to work productivity. Additional questions on demo-
graphics, prior OAB treatment, and daily pad use were asked. A
WPQ Index was computed to estimate productivity impairment
compared to healthy individuals. Characteristics related to pro-
ductivity loss were determined using group comparisons (t-test).
RESULTS: Approximately half (52.7%) of participants were of
working age (18–64 years), and 44.9% were employed. The
majority were female (92.0%) and white (81.2%). Overall,
working participants were approximately 7.9% less productive
than healthy individuals. Group comparisons revealed that
females experienced greater physical limitations than males (p <
0.05) but had similar time, mental, and output scores. Age
younger than 65 was associated with greater impairments of
time, mental, and output domains (p < 0.05 for all). Minorities
(African Americans, Hispanics, and Asians) experienced signiﬁ-
cantly less productivity than whites across all categories with the
exception that African Americans reported similar time impair-
ments to whites. Productivity scores were inversely related to
daily pad use (those using 1- or 2- experiencing higher scores
than those using 3 or more), and did not differ between treat-
ment naïve and those previously treated (p > 0.05 for all
domains). CONCLUSIONS: OAB causes job interruptions, dif-
ﬁculties in adhering to a schedule, physical limitations, impaired
concentration, and reduced ability to handle workload. Females
with OAB experience more physical limitations than males, and
minorities generally experience greater productivity impairments
than whites.
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OBJECTIVES: To identify predictors of off-label utilization of
Erythropoietin and Darbepoetin across hospitals in the United
States. METHODS: A retrospective database (Solucient®) review
was performed on 169,288 discharged patients who received ery-
thropoietin and darbepoetin across 187 hospitals. Based upon
an evidence-based medicine framework, utilization of the two
drugs was categorized as “on-label” (approved by the FDA),
“off-label-supported” (not FDA-approved but with strong evi-
dence supporting off-label use), and “off-label-unsupported”
(minimal literature support for off-label indications). A multin-
omial logistic regression model clustered by hospitals was used.
Model covariates were patient demographics, clinical outcomes,
physician specialty, hospital size, teaching status, region, drug
dose, and number of administrations. RESULTS: Relative to on-
label, physician specialty, patient age group, race, and drug cov-
erage were signiﬁcant (at the 0.05 level) predictors of off-label
use (supported and unsupported). Surgeons were twice as likely
to prescribe off-label-unsupported (OFUS) than generalists 
and four times more likely than specialists. Infants (0–1 years),
{RRR-164; 95%CI, 84–319}, children (1–17 years), {RRR-2.30;
95%CI, 1.45–5.0}, and young-adults (18–24 years) {RRR-2.30,
95%CI, 2.07–3.19} were more likely to receive OFUS compared
to middle-aged adults (40–59 years), while OFUS prescribing 
for individuals over 75 years was weakly predictive (RRR-1.28;
95%CI, 1.03–1.6). African-Americans and Native-Americans
were twice as likely to receive drugs for off-label-supported
(OFS) but half as likely for OFUS use relative to whites. More-
over, Title-V, Worker’s compensation, and self-pay patients were
more likely to receive OFUS. CONCLUSIONS: Variations in off-
label prescribing among physician specialties may reﬂect a lack
of consensus on practice guidelines. The common use of OFUS
prescribing in pediatrics may be explained by the limited clini-
cal trial data on children. Racial differences in OFUS may indi-
cate differing disease prevalence in populations. Knowing causes
of off-label prescribing can help decision makers understand the
degree to which it is appropriate.
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OBJECTIVES: We implemented a focused drug therapy man-
agement intervention aimed at reducing polypharmacy for Med-
icaid recipients in North Carolina nursing homes. Targeted were
patients receiving >18 prescriptions in 90 days. During sched-
uled monthly home visits, consultant pharmacists providing
routine drug regimen reviews also reviewed drug proﬁles dis-
playing claims-generated drug problem alerts. Pharmacists doc-
umented reviews, recommendations and resulting drug therapy
changes. Study objectives were to determine: 1) the frequency
with which potential drug therapy problems (PDTPs) were found
